Literature DB >> 29397594

[Efficacy of probiotics on the treatment of non-alcoholic fatty liver disease].

W Wang1, L P Shi, L Shi, L Xu.   

Abstract

Objective: To study the clinical effect of probiotics in the treatment of non-alcoholic fatty liver disease (NAFLD).
Methods: A total of 200 patients with NAFLD were randomly divided into 4 groups: control group (routine treatment group) and combined treatment group A, B and C. Each group had equal patients. The control group received orally polyene phosphatidylcholine capsules; whereas combined group A, B and C were given orally the live "combined Bifidobacterium Lactobacillus and Enterococcus powder" , "two live combined Bacillus subtilis and Enterococcus" , and the both probiotics respectively. The duration of treatment was 1 month. Laboratory parameters were evaluated before treatment and thirtieth day after treatment, including cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol(LDL-C), alanine aminotransferase(ALT), aspartate aminotransferase (AST), fasting blood glucose (FPG), serum high molecular weight adiponectin (HMW-APN) and serum TNFα. Meanwhile the faece sample was collected for routine test and bacterial culture. Liver ultrasound scan was done in all patients.
Results: In terms of blood lipids and blood glucose, each group improved after treatment with significant differences (P<0.05) except for HDL-C. As for liver function, serum ALT and AST decreased after treatment in each group; especially in combined group C which were lower than those of control group [(33.7±7.6) U/L vs. (45.0±8.5) U/L; (22.0±1.6) U/L vs. (29.4±3.7) U/L; P<0.05]. TNFα levels decreased after treatment in each group, in addition the values in combined group C was significantly lower than that of control group[(0.51±0.27) µg/L vs. (0.82±0.28) µg/L, P<0.05]. Serum HMW-APN increased after treatment in each group, and the HMW-APN in combined C group was significantly higher than that of control group[(9.28±3.72) µg/L vs. (7.87±3.96)µg/L, P<0.05]. (5) After treatment, all groups showed improvement of fatty liver by ultrasound, but the difference between groups was not statistically significant. (6) Compared with before treatment, fecal flora in combined groups was all reduced (P<0.01), but it was comparable before and after treatment in control group. Conclusions: Probiotics improve intestinal microecological system in NAFLD patients via inhibiting TNFα and enhancing adiponectin, possibly resulting in regulating blood glucose, lipid metabolism, and protecting liver injury from NAFLD.

Entities:  

Keywords:  Adiponectin; Non-alcoholic fatty liver disease; Probiotics; Tumor necrosis factor-alpha

Mesh:

Substances:

Year:  2018        PMID: 29397594     DOI: 10.3760/cma.j.issn.0578-1426.2018.02.004

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  12 in total

Review 1.  Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Authors:  Hamed Ebrahimzadeh Leylabadlo; Reza Ghotaslou; Hossein Samadi Kafil; Mohammad Mehdi Feizabadi; Seyed Yaghoub Moaddab; Safar Farajnia; Elham Sheykhsaran; Sarvin Sanaie; Dariush Shanehbandi; Hossein Bannazadeh Baghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-11       Impact factor: 3.267

Review 2.  Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.

Authors:  Liang Liu; Ping Li; Yiqi Liu; Yilian Zhang
Journal:  Dig Dis Sci       Date:  2019-06-15       Impact factor: 3.199

3.  Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Yao Tang; Juan Huang; Wen Yue Zhang; Si Qin; Yi Xuan Yang; Hong Ren; Qin-Bing Yang; Huaidong Hu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-25       Impact factor: 4.409

Review 4.  The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Erica Jennison; Christopher D Byrne
Journal:  Clin Mol Hepatol       Date:  2020-12-10

Review 5.  Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date.

Authors:  Małgorzata Moszak; Monika Szulińska; Marta Walczak-Gałęzewska; Paweł Bogdański
Journal:  Int J Environ Res Public Health       Date:  2021-02-08       Impact factor: 3.390

Review 6.  Role and Mechanism of Gut Microbiota in Human Disease.

Authors:  Yinwei Chen; Jinghua Zhou; Li Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-17       Impact factor: 5.293

7.  Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Oluyemi Komolafe; Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas Jg Chase; Dominic Fritche; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-07-19

8.  Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Xiongfeng Pan; Shi Wu Wen; Atipatsa C Kaminga; Aizhong Liu
Journal:  Sci Rep       Date:  2020-06-01       Impact factor: 4.379

Review 9.  Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?

Authors:  Chencheng Xie; Dina Halegoua-DeMarzio
Journal:  Nutrients       Date:  2019-11-19       Impact factor: 5.717

10.  Protective effect of probiotics in patients with non-alcoholic fatty liver disease.

Authors:  Gen-Shen Cai; Hui Su; Jing Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.